Updates on use of Tixagevimab-Cilgavimab (Evusheld)

The following updates have been approved by the Pharmacy & Therapeutics Committee effective June 21, 2022, for the use of Tixagevimab-Cilgavimab (Evusheld) in adult and pediatric patients. Interim Guidance for the Use of Tixagevimab-Cilgavimab (Evusheld) in Adult Patients Interim Guidance for the Use of Tixagevimab Cilgavimab (Evusheld) in Pediatric Patients If you have questions, please… Read More

Updated pharmacotherapy guidelines

The Pharmacy &  Therapeutics Committee has approved the following updates to our interim pharmacotherapy guidance: Interim Pharmacotherapy Guidance for SARS-CoV-2 (COVID-19) Infection in Hospitalized Adult Patients (updated 5-17-2022) Interim Pharmacotherapy Guidance for the Inpatient Management of SARS-CoV-2 (COVID-19) Infection of Pediatric Patients (updated 5-17-2022)

Updated pharmacotherapy guidance for adult and pediatric patients

The UK HealthCare Pharmacy & Therapeutics Committee has approved the following updates and additions to interim guidance for adult and pediatric patients. New guidelines Interim Guidance for the Use of Tixagevimab-Cilgavimab (Evusheld) in Adult Patients (4-19-22) Interim Guidance for the Use of Tixagevimab-Cilgavimab (Evusheld) in Pediatric Patients (4-22-22) Interim Pharmacotherapy Guidance for SARS-CoV-2 (COVID-19) Infection… Read More

Update to limited-supply adult treatment options for omicron variant

Due to the rising number of positive cases, limited available treatments and abundant vaccine supply, we continue to encourage patients and community members to be vaccinated.  Monoclonal Antibodies As of Thursday, December 30, UK HealthCare has used allotted doses of all adult monoclonal antibodies, and the therapy plan has been removed from Epic as an order. The… Read More